Figure 2.

Adjustments to the muscles targeted and the dose of onabotulinumtoxinA utilized by clinicians at the time of re‐treatment in the lower limb population. At the time of re‐treatment, clinicians were asked whether (A) the muscles treated changed and (B) if the dose of onabotulinumtoxinA was adjusted from the last treatment session (shown in the black box). Of those that responded “yes” to the above questions, the three most common reasons cited by clinicians for this decision (excluding “other”) are provided in rank order (shown in the gray box). Clinicians could select more than one reason. n, number of treatment sessions; Tx, treatment session.